{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:48:53Z","timestamp":1793137733196,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41591-024-03462-0","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:04:50Z","timestamp":1737108290000},"page":"909-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Alicia F. C.","family":"Okines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9704-1885","authenticated-orcid":false,"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andree","family":"Rorive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-2264","authenticated-orcid":false,"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-1699","authenticated-orcid":false,"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Burkard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Y.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-9697","authenticated-orcid":false,"given":"Philip R.","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny R.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-5355","authenticated-orcid":false,"given":"Marta","family":"Gil-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-0336","authenticated-orcid":false,"given":"Erika P.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-6855","authenticated-orcid":false,"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-2271","authenticated-orcid":false,"given":"Danny","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Van Marcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-8011","authenticated-orcid":false,"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7914-5162","authenticated-orcid":false,"given":"Paula R.","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"3462_CR1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","volume":"20","author":"DJ Riese 2nd","year":"1998","unstructured":"Riese, D. J. 2nd & Stern, D. F. Specificity within the EGF family\/ErbB receptor family signaling network. Bioessays 20, 41\u201348 (1998).","journal-title":"Bioessays"},{"key":"3462_CR2","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"MA Olayioye","year":"2000","unstructured":"Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159\u20133167 (2000).","journal-title":"EMBO J."},{"key":"3462_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127\u2013137 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3462_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","volume":"110","author":"J Schlessinger","year":"2002","unstructured":"Schlessinger, J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110, 669\u2013672 (2002).","journal-title":"Cell"},{"key":"3462_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.pharmtox.44.101802.121440","volume":"44","author":"T Holbro","year":"2004","unstructured":"Holbro, T. & Hynes, N. E. ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44, 195\u2013217 (2004).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"3462_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341\u2013354 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"3462_CR7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109\u2013119 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"3462_CR10","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-021-01553-w","volume":"27","author":"Y Nakamura","year":"2021","unstructured":"Nakamura, Y. et al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat. Med. 27, 1899\u20131903 (2021).","journal-title":"Nat. Med."},{"key":"3462_CR11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382, 597\u2013609 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","volume":"24","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496\u2013508 (2023).","journal-title":"Lancet Oncol."},{"key":"3462_CR13","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR14","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419\u20132430 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop, I. E. et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 18, 743\u2013754 (2017).","journal-title":"Lancet Oncol."},{"key":"3462_CR16","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s12282-015-0659-y","volume":"23","author":"Y Endo","year":"2016","unstructured":"Endo, Y. et al. HER2 mutation status in Japanese HER2-positive breast cancer patients. Breast Cancer 23, 902\u2013907 (2016).","journal-title":"Breast Cancer"},{"key":"3462_CR17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman, D. M. et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554, 189\u2013194 (2018).","journal-title":"Nature"},{"key":"3462_CR18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/modpathol.2011.64","volume":"24","author":"T Khoury","year":"2011","unstructured":"Khoury, T. et al. ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene. Mod. Pathol. 24, 1055\u20131059 (2011).","journal-title":"Mod. Pathol."},{"key":"3462_CR19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.molonc.2014.10.011","volume":"9","author":"DR Boulbes","year":"2015","unstructured":"Boulbes, D. R. et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol. Oncol. 9, 586\u2013600 (2015).","journal-title":"Mol. Oncol."},{"key":"3462_CR20","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-15-3036","volume":"22","author":"WJ Zuo","year":"2016","unstructured":"Zuo, W. J. et al. Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer. Clin. Cancer Res. 22, 4859\u20134869 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3462_CR21","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/1078-0432.CCR-18-4055","volume":"25","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Parallel analyses of somatic mutations in plasma circulating tumor DNA (ctDNA) and matched tumor tissues in early-stage breast cancer. Clin. Cancer Res. 25, 6546\u20136553 (2019).","journal-title":"Clin. Cancer Res."},{"key":"3462_CR22","doi-asserted-by":"crossref","first-page":"e000279","DOI":"10.1136\/esmoopen-2017-000279","volume":"2","author":"CM Connell","year":"2017","unstructured":"Connell, C. M. & Doherty, G. J. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2, e000279 (2017).","journal-title":"ESMO Open"},{"key":"3462_CR23","doi-asserted-by":"crossref","first-page":"73337","DOI":"10.18632\/oncotarget.11819","volume":"7","author":"G Deniziaut","year":"2016","unstructured":"Deniziaut, G. et al. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget 7, 73337\u201373346 (2016).","journal-title":"Oncotarget"},{"key":"3462_CR24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10555-022-10021-x","volume":"41","author":"CS Wynn","year":"2022","unstructured":"Wynn, C. S. & Tang, S. C. Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer Metastasis Rev. 41, 193\u2013209 (2022).","journal-title":"Cancer Metastasis Rev."},{"key":"3462_CR25","first-page":"S459","volume":"34","author":"BT Li","year":"2023","unstructured":"Li, B. T. et al. 654O efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Ann. Oncol. 34, S459\u2013S460 (2023).","journal-title":"Ann. Oncol."},{"key":"3462_CR26","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1093\/oncolo\/oyad122","volume":"28","author":"H Tian","year":"2023","unstructured":"Tian, H. et al. Dramatic response to pyrotinib and T-DM1 in HER2-negative metastatic breast cancer with 2 activating HER2 mutations. Oncologist 28, e534\u2013e541 (2023).","journal-title":"Oncologist"},{"key":"3462_CR27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","volume":"34","author":"K Jhaveri","year":"2023","unstructured":"Jhaveri, K. et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann. Oncol. 34, 885\u2013898 (2023).","journal-title":"Ann. Oncol."},{"key":"3462_CR28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian, A. et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol. Cancer Ther. 19, 976\u2013987 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"3462_CR29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"G Curigliano","year":"2022","unstructured":"Curigliano, G. et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol. 33, 321\u2013329 (2022).","journal-title":"Ann. Oncol."},{"key":"3462_CR30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin, N. U. et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J. Clin. Oncol. 38, 2610\u20132619 (2020).","journal-title":"J. Clin. Oncol."},{"key":"3462_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","volume":"9","author":"NU Lin","year":"2023","unstructured":"Lin, N. U. et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9, 197\u2013205 (2023).","journal-title":"JAMA Oncol."},{"key":"3462_CR32","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1158\/1538-7445.AM2020-4222","volume":"80","author":"S Peterson","year":"2020","unstructured":"Peterson, S., Rosler, R. & Klucher, K. Abstract 4222: Tucatinib, a selective small molecule HER2 inibitor, is active in HER2 mutant driven tumors. Cancer Res. 80, 4222 (2020).","journal-title":"Cancer Res."},{"key":"3462_CR33","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR34","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733\u20132743 (2006).","journal-title":"N. Engl. J. Med."},{"key":"3462_CR35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/PO.20.00469","volume":"5","author":"EG Sturgill","year":"2021","unstructured":"Sturgill, E. G. et al. Next-generation sequencing of patients with breast cancer in community oncology clinics. JCO Precis. Oncol. 5, 1297\u20131311 (2021).","journal-title":"JCO Precis. Oncol."},{"key":"3462_CR36","doi-asserted-by":"crossref","first-page":"abstr. 3528","DOI":"10.1200\/JCO.2023.41.16_suppl.3528","volume":"41","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. HER2 testing in the MOUNTAINEER trial: analysis of treatment response based on central HER2 assessment using IHC\/ISH and NGS. J. Clin. Oncol. 41, abstr. 3528 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3462_CR37","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","volume":"41","author":"Y Nakamura","year":"2023","unstructured":"Nakamura, Y. et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study. J. Clin. Oncol. 41, 5569\u20135578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3462_CR38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","volume":"34","author":"KB Pahuja","year":"2018","unstructured":"Pahuja, K. B. et al. Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell 34, 792\u2013806.e5 (2018).","journal-title":"Cancer Cell"},{"key":"3462_CR39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","volume":"36","author":"JP Robichaux","year":"2019","unstructured":"Robichaux, J. P. et al. Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity. Cancer Cell 36, 444\u2013457.e447 (2019).","journal-title":"Cancer Cell"},{"key":"3462_CR40","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404\u2013413 (1934).","journal-title":"Biometrika"},{"key":"3462_CR41","doi-asserted-by":"crossref","unstructured":"Collett, D. in Modelling Survival Data in Medical Research (ed. Collett, D.) 2nd edn, 237\u2013251 (Chapman & Hall, 1994).","DOI":"10.1007\/978-1-4899-3115-3_8"},{"key":"3462_CR42","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03462-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T12:26:38Z","timestamp":1742387198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3462"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03462-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.F.C.O. reports research funding from Pfizer and Roche; honoraria for presentations from AstraZeneca, Esai, Gilead, Lilly, Pfizer, Roche and Seagen; advisory board fees from AstraZeneca, Pfizer, Roche and Seagen; and conference support from AstraZeneca, Lilly, Novartis and Roche. G.C. reports consulting or advisory roles with AstraZeneca, Celucity, Daiichi Sankyo, Ellipsis, Exact Sciences, Gilead, Lilly, MBS, Menarini, Merck, Pfizer, Roche and Veracyte; institutional research funding from Astellas, AstraZeneca, Blueprint Medicine, BMS, Daiichi Sankyo, Kymab, Merck, Novartis, Philogen, Relay Therapeutics, Roche and Sanofi; speaker fees from AstraZeneca, Daiichi Sankyo, Novartis, Pfizer and Roche; and writing engagement with Pfizer. N.M. reports grants or contracts to the institution from AstraZeneca, Boehringer Ingelheim, Incyte, MSD, Novartis, Ono Pharmaceutical, Pfizer and Seagen; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, paper writing or educational events from AstraZeneca, FujiFilm Toyama Chemical, Miyarisan Pharmaceutical, Novartis, Taiho Pharmaceutical and Yakult Honsha; and data safety monitoring or advisory board roles with AstraZeneca and Boehringer Ingelheim. D.-Y.O. reports research funding from Array BioPharma, AstraZeneca, BeiGene, Eli Lilly, Handok, MSD, Novartis and Servier, and consulting or advisory roles with Arcus Biosciences, ASLAN Pharmaceuticals, AstraZeneca, Basilea, Bayer, BeiGene, Celgene, Genentech\/Roche, Halozyme, IQVIA, Merck Serono, MSD Oncology, Novartis, Taiho Pharmaceutical, Turning Point Therapeutics, Yuhan and Zymeworks. H.S. reports institutional research funding from Amgen; consulting fees from AstraZeneca, Celgene, Eisai, Novartis, PUMA, Seattle Genetics, Sanofi and Sermonix; advisory board roles with AstraZeneca, Eisai, Eli Lilly, Novartis and PUMA; speaker fees from Merck; and licensing fees for intellectual property from Celyad Oncology. S. Takahashi reports grants and\/or personal fees from AstraZeneca, Bayer, Chugai, Daiichi Sankyo, Eisai, MSD, Novartis and Taiho. T.B.-S. reports institutional research funding from Abgenomics, Agios, Arcus, Arys, Atreca, Bayer, BMS, Boston Biomedical, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer and Seagen; institutional consulting fees from Arcus, Bayer, Eisai, Incyte, Ipsen, Genentech, Merck KGaA, Merck, Merus, Pfizer, Seagen and Servier; personal consulting fees from AbbVie, Aptitude Health, AstraZeneca, Beigene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Science, Exelixis, Foundation Medicine, GlaxoSmithKline, Illumina, Janssen, Kanaph, MJH Life Sciences, Natera, Sanofi, Sobi, Stemline, TreosBio, Xilio and Zai Labs; IDMC\/DSMB roles with 1Globe, AstraZeneca, Exelixis, Fibrogen, Merck\/Eisai, PanCan, Suzhou Kintor and The Valley Hospital; consulting or advisory board roles with Artiva, Bard, Immuneering, Imugene, Replimune, Sun Biopharma and Xilis; and patents WO\/2018\/183488: Human PD1 peptide vaccines and uses thereof, licensed to Imugene, and WO\/2019\/055687: Methods and compositions for the treatment of cancer cachexia, licensed to Recursion. M.E.B. reports consulting or advisory roles with LifeOmic, Novartis and Strata Oncology; institutional research funding from AbbVie, Apollomics, Arcus Ventures, Elevation Oncology, Endeavor BioMedicines, Genentech, Loxo, Merck, Puma Biotechnology, Seagen and Strata Oncology; travel, accommodations and expenses from LifeOmic; and patents, royalties and other intellectual property: patents for (1) an implantable and localized drug delivery device that can sample the tumor microenvironment and deliver the drug, (2) a method to detect recombination events with CRISPR-mediated editing and (3) expansion microscopy without specialized equipment. K.Y.C. reports institutional research funding from Epizyme+L20 and MedImmune. P.R.D. reports institutional grants from Pfizer; advisory board roles with Astellas Pharma, BMS, Ipsen, Merck and Pfizer; honoraria for lectures from Bayer; travel support from Janssen; and a role as a substitute board member for the Clinical Trials College, Federal Public Service, Kingdom of Belgium; and holds stocks in Alkermes, Mural Oncology PLC and Biocartis Group NV. V.G. reports research funding from Bayer, Boehringer and Roche and institutional funding from Amcure, Astelas, AstraZeneca, Bayer, BeiGene, BMS, FibroGen, Genentech, Lilly, Medimmune, Merck Serono, MSD, Natera, Novartis, Roche, Servier, Sierra Oncology and Takeda. M.G.-M. reports a consulting or advisory role with AstraZeneca and travel, accommodation and expenses from GlaxoSmithKline and MSD Oncology. E.P.H. reports advisory and consulting roles (all payments to the institution) with Accutar Biotechnology, AstraZeneca, Daiichi Sankyo, Eli Lilly, Ellipses Pharma, Entos, Fosun Pharma, Genentech\/Roche, Gilead Sciences, Jazz Pharmaceuticals, Jefferies LLC, Medical Pharma Services, Mersana, Novartis, Olema Pharmaceuticals, Pfizer, Stemline Therapeutics, Tempus Labs, Theratechnologies, Tubulis, Verascity Science and Zentalis Pharmaceuticals and institutional research funding from Abbvie, Accutar Biotechnology, Acerta Pharma, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Eli Lilly, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, FujiFilm, G1 Therapeutics, Genentech\/Roche, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, ProfoundBio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, StemCentRx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics and Zymeworks. B.J.M. reports honorarium for consulting or speaking from Acrivon, Adaptimmune, Agenus, Akeso Bio, Amgen, AstraZeneca, Biohaven, BMS, Corcept, Easai, Eli Lilly, Genalux, Genmab\/Seagen\/Pfizer, GOG Foundation, Gradalis, GSK, Heng Rui, Immunogen\/Abbvie, Iovance, Karyopharm, Merck, Mersana, Mural\/Alkermes, Myriad, Novartis, Novocure, OncoC4, Panavance, ProfoundBio, Regeneron, Roche\/Genentech, Sutro, Verastem, Zentalis and Zymeworks. Y.N. reports consulting or advisory roles with Daiichi Sankyo, Exact Sciences, Gilead Sciences, Guardant Health, Natera, Premo Partners, Roche, Seagen and Takeda; participation in speakers\u2019 bureau for Becton Dickinson, CareNet, Chugai Pharma, Daiichi Sankyo, Eisai, Guardant Health, Guardant Health Japan, Hisamitsu Pharmaceutical, Merck, Miyarisan Pharmaceutical, MSD KK, Taiho Pharmaceutical and Zeria Pharmaceutical; and institutional research funding from Chugai Pharma, Daiichi Sankyo, Genomedia, Guardant Health, Guardant Health AMEA, Roche Diagnostics KK, Seagen and Tempus. D.N. reports a consulting or advisory role with Janssen Oncology; stock and other ownership interests in Intuitive Surgical and Teladoc; and financial interests with Novartis and Takeda. D.M.O. reports consulting or advisory roles with Adaptimmune, Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, DualityBio, Eisai, Elevar Therapeutics, GlaxoSmithKline, GOG Foundation, Immunogen, Imvax, Laekna Therapeutics, Merck, Mersana, Novartis, Novocure, OncoC4, Onconova Therapeutics, Regeneron, Roche, Seagen, Sutro Biopharma, Umoja Biopharma and Verastem and institutional research funding from AbbVie, AbbVie\/Stemcentrx, Acerta Pharma, Advaxis, Ajinomoto, Amgen, AstraZeneca, Arcus Biosciences, Array BioPharma, BBI Healthcare, BeiGene, Bristol Myers Squibb, Cerulean Pharma, Clovis Oncology, Deciphera, Eisai, EMD Serono, Ergomed, Exelixis, Genentech\/Roche, Genmab, GlaxoSmithKline, OncoQuest, Pfizer, Precision Therapeutics, Immunogen, Incyte, Iovance Biotherapeutics, Janssen Research & Development, Karyopharm Therapeutics, Leap Therapeutics, Ludwig Institute for Cancer Research, Merck, Mersana, Novartis, NovoCure, PharmaMar, Regeneron, Roche, Sanofi, Seagen, Sumitomo Dainippon Pharma Oncology, Sutro Biopharma, Tesaro, TRACON Pharma and Verastem. A.B.O. reports consulting or advisory roles with AstraZeneca, Clovis Oncology, Genentech, GlaxoSmithKline, Novocure and Tesaro. M.R. reports honoraria for lectures and consultancy from Amgen, AstraZeneca, BMS, BeiGene, Boehringer Ingelheim, Daiichi Sankyo, GSK, Lilly, Merck, Mirati, MSD, Novartis, Pfizer, Regeneron and Sanofi; and compensation for membership in DMSB by Daiichi Sankyo and Sanofi. K.S. reports research funds from AstraZeneca, Amgen, Daiichi Sankyo, Gilead, Merck, NanoCarrier, PRA Health Sciences and Takeda; and personal fees from AstraZeneca, Bayer Yakuhin, Eisai, MSD, Nihon Medi-Physics and Pfizer. Y.S. reports institutional grants or contracts from Chugai and Taiho; payment or honoraria for lectures, presentations, speaker\u2019s bureau, paper writing or educational events from Astellas, Bayer Yakuhin, Bristol Myers Squibb KK, Chugai, Daiichi Sankyo, Eli Lilly Japan KK, Guardant Health, Merck, MSD KK, Novartis, Ono, Sysmex, Taiho and Takeda; and roles on data safety monitoring or advisory boards with Guardant Health, Merck and Ono. C.V.M. reports institutional research funding from DigiCore and Gilead; consulting or advisory roles (to the institution) from AstraZeneca, Daiichi Sankyo, Lilly, MSD and Novartis; travel, accommodations and expenses from Amgen, Astellas, Bristol Myers Squibb, DigiCore, Gilead, Merck, MSD Oncology, Pfizer and Roche; and institutional research funding from all companies above. E.Y.Y. reports consulting or advisory roles with AADi, Advanced Accelerator Applications, Bayer, Janssen, Merck and Oncternal Therapeutics; institutional research funding from Agensys, Bayer, Blue Earth Diagnostics, Daiichi Sankyo, Dendreon, Lantheus Medical Imaging, Merck, Seagen, Surface Oncology, Taiho Pharmaceutical and Tyra Biosciences; personal fees from Aadi Bioscience, Advanced Accelerator Applications, Janssen and Oncterna; and grants and personal fees from Bayer and Merck. J.R. reports employment at Pfizer; stock and other ownership interests in Pfizer; and travel and accommodation expenses from Pfizer. S. Tan reports employment at Pfizer; stock and other ownership interests in Pfizer; and travel and accommodation expenses from Pfizer. M.B. reports employment at Pfizer, and stock and other ownership interests in Pfizer. T.E.S. reports consulting or advisory roles with Abbvie, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Coherus Biosciences, G1 Therapeutics, Gilead Sciences, Pfizer, Spectrum Pharmaceuticals and Takeda and institutional research funding from AstraZeneca, Genentech\/Roche, Mirati Therapeutics, Nuvalent, and Seagen. P.R.P. reports honoraria from Dava Oncology, OncLive and Frontiers; consulting or Advisory Role with Personalized Cancer Therapy, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, Heron, Puma Biotechnology, Sirtex Medical, Caris Life Sciences, Juniper Pharmaceuticals, Bolt Biotherapeutics and AbbVie; speakers\u2019 bureau with Genentech\/Roche; institutional research funding from Genentech\/Roche, Fabre-Kramer, Advanced Cancer Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, Cascadian Therapeutics, Bolt Biotherapeutics, Byondis, Seagen, Orum and Carisma; and intellectual property US patent numbers 8,486,413, 8,501,417, 9,023,362 and 9,745,377. Non-financial interests: G.C. reports uncompensated relationships with Consiglio Superiore di Sanit\u00e0 (officer), Italian National Health Council (advisor for the Ministry of Health), ESMO (officer), ESMO Open (editor in chief), Europa Donna (advisory role), member of the Scientific Council Patient Advocacy Association, EUSOMA (leadership role) and Fondazione Beretta (advisory role) Cancer Research Foundation. A.R. reports research funding from Bristol Myers Squibb; payment or honoraria from Bristol Myers Squibb and Novartis; and support for attending meetings and\/or travel from Bristol Myers Squibb, Merck Sharp & Dohme and Novartis. D.N. reports uncompensated relationships with Takeda and Novartis. C.V.M. reports a non-financial competing interest as a board member of BSMO. P.R.P. reports uncompensated relationships with Pfizer, Seagen and Jazz.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}